- Open
- 11.25
- High
- 11.05
- Low
- 10.05
- Close
- 10.07
- Change
- -1.25 (-11.11%)
- Volume
- 1,021,708
| 10 Sept 2026 | 07:00:05 | Investor Presentation of Phase 3 Topline Results |
| 7 Sept 2026 | 07:00:11 | Largest Private Mexican Network Pilots Steriwave |
| 4 Sept 2026 | 07:00:02 | Notification of major holdings |
| 3 Sept 2026 | 09:59:32 | Notification of major holdings - Pentwater |
| 1 Sept 2026 | 07:00:20 | Positive Topline Results in US Phase 3 Study |
Ondine Biomedical Inc. develops light-activated antimicrobial therapies, primarily focusing on its lead product, Steriwave®, which is designed for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. The company operates in the life sciences sector, generating revenue through the commercialization of its photodisinfection technology, which is authorized for nasal decolonization in Canada and certain international markets. Ondine's business model includes conducting clinical trials, such as the Phase 3 LANTERN study in the U.S., and expanding its presence in hospitals and surgical clinics across North America and Europe.
| 10 Sept 2026 | 07:00:05 | Investor Presentation of Phase 3 Topline Results |
| 7 Sept 2026 | 07:00:11 | Largest Private Mexican Network Pilots Steriwave |
| 4 Sept 2026 | 07:00:02 | Notification of major holdings |
| 3 Sept 2026 | 09:59:32 | Notification of major holdings - Pentwater |
| 1 Sept 2026 | 07:00:20 | Positive Topline Results in US Phase 3 Study |
Ondine Biomedical Inc. develops light-activated antimicrobial therapies, primarily focusing on its lead product, Steriwave®, which is designed for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. The company operates in the life sciences sector, generating revenue through the commercialization of its photodisinfection technology, which is authorized for nasal decolonization in Canada and certain international markets. Ondine's business model includes conducting clinical trials, such as the Phase 3 LANTERN study in the U.S., and expanding its presence in hospitals and surgical clinics across North America and Europe.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £4.24bn | -0.1% | |
| £273m | -0.1% | |
OBIOndine Biomedical Inc. | £57m | -0.3% |
| £47m | -0.3% | |
| £32m | +0.1% | |
| £23m | -0.7% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £4.24bn | -0.1% | |
| £273m | -0.1% | |
OBIOndine Biomedical Inc. | £57m | -0.3% |
| £47m | -0.3% | |
| £32m | +0.1% | |
| £23m | -0.7% |